Cell and Gene Therapy Manufacturers Collaborate with Automation Partners
Cell and gene therapy companies are increasingly partnering with specialized technology firms to address the challenges of scaling complex therapies. These collaborations integrate robotics, digital systems, and advanced manufacturing platforms into production workflows for more scalable and efficient processes. Recent partnerships include Cellares working with TScan Therapeutics on automated clinical manufacturing using its FDA-designated Cell Shuttle platform. Other notable alliances involve OmniaBio evaluating Avectas' cell therapy automation system to support a hub-and-spoke model, while Fresenius Kabi and Cellular Origins combine existing technologies with robotic platforms for scalable solutions. These developments reflect growing industry confidence in automated systems as essential tools for late-stage clinical development and commercial production. Companies are integrating these innovations into current workflows rather than replacing them entirely, aiming to create more flexible manufacturing models.
Tickers: $TCRX
Topics: automation CDMO partnerships cell and gene therapy manufacturing innovation